07.30.26 -- Drug Sponsors Are Reshaping Today's CDMOs

Explore innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.

Discover how whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.

Operational excellence relies on strong quality foundations that sustain speed and flexibility. Rigorous standards reduce risk, accelerate progress, and build the trust needed for lasting success.

Supply chain visibility and proactive risk strategies are vital to navigate new federal biotech restrictions and protect drug development pipelines.

Uncover challenges in today’s changing market and solutions to help successfully develop and manufacture lifesaving products.

Predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

To align with Annex 1 expectations, sponsors should focus on three key steps: understanding the guidelines, selecting the right partners, and futureproofing their manufacturing strategies.

Understanding drug substance vs. drug product responsibilities helps avoid regulatory issues, technical risks, and delays while improving planning, scalability, and GMP‑compliant execution.

Turn your inconsistent bioassays into GMP-validated, high-reliability platforms — just like we helped a biopharma partner cut failure rates from ~25% to <1%.

Gain practical guidance for advancing bRo5 candidates through improved permeability and metabolic stability with insights on ECCS classes 3 and 4, optimized in vitro tools, and design principles.

GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

As capacity expands and capabilities mature, CDMOs with global scale and advanced injectable expertise are becoming critical partners for bringing complex sterile drug products to market.

Batch failures in biopharma remain costly despite improvements. Learn the leading causes in downstream purification and how supplier expertise can help reduce risk and protect production.

Antibody-drug conjugates (ADCs) combine antibody targeting with potent cytotoxic payloads to treat resistant cancers, but their complexity requires phase-appropriate analytical strategies.